EICHORCondition: B Cell Lymphoma · Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
This is an open-label phase1 study to assess the safety and efficacy of U01(ssCART-19) cell therapy in the treatment of patients with refractory or recurrent B-cell lymphoma .
This description comes directly from the study's public registry record.
Wenjun Zhang, Doctor · +86 13918803148 · zhangwenjun@tongji.edu.cn
Always discuss trial participation with your own doctor first.
| Shanghai Tongji Hospital ( Tongji Hospital of Tongji University) | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06987916